Skip to main content
Livermore
Livermore
ZHEN

Eikon Therapeutics, Inc.

EIKN
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001861123

In the last 90 days, Eikon Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 77 institutions reported holding it in 13F filings for Q2 2026, worth $344.1M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Eikon Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
1 filing
1 insider, $1.03M in total
Open-market sells
0 filings
Insiders trading
1
Net value
+$1.03M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Eikon Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Eikon Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Svennilson Peter10% Owner89,200IndirectSep 8, 20262
Kutzkey Tim10% Owner89,200IndirectSep 8, 20262
Column Group IV-A, LP10% Owner89,200IndirectSep 8, 20262
Column Group IV, LP10% Owner89,200IndirectSep 8, 20262
Column Group IV GP, LP10% Owner89,200IndirectSep 8, 20262
Column Group Opportunity III, LP10% Owner89,200IndirectSep 8, 20262
TCG Opportunity III GP, LLC10% Owner89,200IndirectSep 8, 20262
Column Group Opportunity III GP, LP10% Owner89,200IndirectSep 8, 20262
Frazier Kenneth CDirector111,111Mar 4, 20262
Perlmutter Roger MSee remarks284,857IndirectMar 4, 20262
Baynes Roy D.Chief Medical Officer–Mar 4, 20261
Huffines Robert LutherDirector–Mar 4, 20261
Klobuchar Michael AChief Operating Officer–Mar 4, 20261
Thorner Benjamin BrunoSee Remarks–Mar 4, 20261
Bowie Alfred Lloyd Jr.Chief Financial Officer–Mar 4, 20261
Foresite Capital Fund IV, L.P.10% Owner1,318,983IndirectFeb 6, 20261
Foresite Capital Management IV, LLC10% Owner1,318,983IndirectFeb 6, 20261
Foresite Capital Fund V, L.P.10% Owner1,318,983IndirectFeb 6, 20261
Foresite Capital Opportunity Fund V, L.P.10% Owner1,318,983IndirectFeb 6, 20261
Foresite Capital Management V, LLC10% Owner1,318,983IndirectFeb 6, 20261
Foresite Capital Opportunity Management V, LLC10% Owner1,318,983IndirectFeb 6, 20261
Foresite Capital VI-A, LLC10% Owner1,318,983IndirectFeb 6, 20261
Foresite Capital VI-A Management, LLC10% Owner1,318,983IndirectFeb 6, 20261
Hebert Peter10% Owner2,294,653IndirectFeb 6, 20261
Lux Ventures V, L.P.10% Owner2,294,653IndirectFeb 6, 20261
Lux Venture Partners V, LLC10% Owner2,294,653IndirectFeb 6, 20261
Lux Co-Invest Opportunities II, L.P.10% Owner2,294,653IndirectFeb 6, 20261
Wolfe JoshDirector, 10% Owner2,294,653IndirectFeb 6, 20262
Lux Total Opportunities, L.P.10% Owner2,294,653IndirectFeb 6, 20261

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 8, 2026 (view filing)4:33 PM ETSep 35 daysSvennilson Peter and 7 others10% OwnerPPurchase+89.2K$11.56+$1.03MNew position89.2K after
Feb 9, 2026 (view filing)9:19 PM ETFeb 63 daysSvennilson Peter and 7 others10% OwnerPPurchase+2.12M$18.00+$38.1MNew position1.32M after3 lots
Feb 6, 2026 (view filing)7:37 PM ETFeb 42 daysForesite Capital Fund IV, L.P. and 7 others10% OwnerPPurchase+55.6K$18.00+$1.00M+4.4%1.32M after
Feb 6, 2026 (view filing)6:25 PM ETFeb 42 daysWolfe Josh and 5 othersDirector, 10% OwnerPPurchase+277.8K$18.00+$5.00MNew position138.9K after2 lotsDuplicate filing
Feb 6, 2026 (view filing)Feb 42 daysFrazier Kenneth CDirectorPPurchase+111.1K$18.00+$2.00MNew position111.1K after
Feb 6, 2026 (view filing)Feb 42 daysWolfe JoshDirector, 10% OwnerPPurchase+277.8K$18.00+$5.00MNew position138.9K after2 lots